U.S. Infrastructure Stock News

NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative

Relay Therapeutics FY 2025 earnings: revenue modest, losses continue as investors focus on growth potential Relay Therapeutics (RLAY) has wrapped up FY 2025 with Q4 revenue of US$7 million, a basic EPS loss of US$0.32, and net income loss of US$54.89 million, keeping the story firmly in loss-making territory as the market weighs its growth profile. The company has seen quarterly revenue move between US$0 million and US$7.68 million over the past year, while basic EPS losses have ranged from...
NYSE:FERG
NYSE:FERGTrade Distributors

Does Ferguson’s 2026 Outlook and Capital Returns Shift the Bull Case For Ferguson (FERG)?

In late February 2026, Ferguson Enterprises Inc. reported past fourth-quarter sales of US$7,495 million and net income of US$389 million, alongside five‑month sales of US$12,833 million and net income of US$786 million, while also outlining low‑ to mid‑single‑digit net sales growth expectations for the 2026 calendar year. Along with these results, Ferguson continued to return cash to shareholders through US$248.45 million of share repurchases completing a multi‑year US$4.49 billion program...
NYSE:CYD
NYSE:CYDMachinery

Is China Yuchai International (CYD) Quietly Rewriting Its Engine Mix And Overseas Playbook?

China Yuchai International Limited has reported its 2025 full-year results, with sales rising to CNY 24,661.77 million and net income increasing to CNY 537.39 million, alongside higher basic and diluted earnings per share from continuing operations at CNY 14.32. Beyond the headline growth, the company’s performance was underpinned by heavier exposure to high-horsepower and heavy-duty engines, overseas expansion, and higher R&D spending on new energy technologies and advanced...
NYSE:EXPD
NYSE:EXPDLogistics

Does Expeditors (EXPD) Prioritize Buybacks Over Operational Resilience Amid Softer Ocean Freight Trends?

In February 2026, Expeditors International of Washington reported fourth-quarter 2025 results showing revenue of US$2,855.95 million and net income of US$200.71 million, alongside authorizing a new US$3.00 billion share repurchase program and completing a long-running US$8.72 billion buyback. While full-year 2025 revenue and earnings per share grew modestly, weaker ocean freight performance and higher headcount weighed on quarterly profitability. We will now examine how softer ocean freight...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data

Conference update and pipeline focus Corvus Pharmaceuticals (CRVS) has come into focus after its appearance at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management outlined fresh details on lead candidate soquelitinib across several immune related indications. The company highlighted plans for a phase III interim analysis in peripheral T cell lymphoma by year end 2026, new phase II studies in asthma and hidradenitis suppurativa, and early atopic dermatitis data...
NasdaqGS:CENT
NasdaqGS:CENTHousehold Products

Central Garden And Pet Weighs Revenue Pressure Against Buybacks And Board Shift

Central Garden & Pet reported a 6% year over year revenue decline in its latest quarter. The company expanded its share repurchase program, signaling an increased focus on buybacks. Central Garden & Pet also refreshed its board of directors with new appointments. Central Garden & Pet, traded as NasdaqGS:CENT, released results that showed weaker revenue and earnings alongside the slowest revenue growth among its household product peers. The stock last closed at $39.18 and is up 22.1% over...
NYSE:UHS
NYSE:UHSHealthcare

Is It Time To Reassess Universal Health Services (UHS) After Recent Share Price Weakness?

If you are wondering whether Universal Health Services is attractively priced or starting to look expensive, you are in the right place for a clear look at what the market might be implying about its value. The shares last closed at US$206.10, with returns of a 10.6% decline over 7 days, 1.5% over 30 days, a 6.3% decline year to date, 18.1% over 1 year, 64.2% over 3 years, and 61.1% over 5 years. This gives you a broad sense of how sentiment around the stock has shifted over time. Recent...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

ON Semiconductor Resets Portfolio Toward Silicon Carbide And AI Power Growth

ON Semiconductor is sharpening its focus on higher margin areas, including silicon carbide products and AI data center power solutions. The company is reallocating capital toward projects it views as higher return and scaling back exposure to weaker end markets such as electric vehicles and smartphones. Management is emphasizing capital discipline and targeted investment as it reshapes the business mix of NasdaqGS:ON. For investors tracking NasdaqGS:ON, this reset comes with the stock...
NasdaqGS:CCB
NasdaqGS:CCBBanks

Why Coastal Financial (CCB) Is Down 11.3% After Revenue Miss Despite Loan And Deposit Growth

Coastal Financial recently reported a past-quarter update showing a 1.3% year-on-year revenue decline, missing analysts’ expectations by 16.6%, even as loans receivable grew 1.2% and deposits rose 4.3%. Management emphasized the potential of its Banking-as-a-Service platform, highlighting plans to expand product offerings and scale new and existing partnerships despite the disappointing revenue and net interest income performance. We’ll now examine how Coastal Financial’s revenue shortfall...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)

Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date. Alongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...
NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding Plans - Has The Bull Case Changed?

Pulse Biosciences, Inc. reported a full-year 2025 net loss of US$72.78 million, widening from US$53.59 million in 2024, and filed new universal and ESOP-related shelf registrations alongside a reconfigured at-the-market common stock offering. At the same time, FDA approval to begin a paroxysmal atrial fibrillation study with the nPulse Cardiac Catheter System and a planned thyroid cancer collaboration with The University of Texas MD Anderson Cancer Center underscore how the company is...
NasdaqGS:HNST
NasdaqGS:HNSTPersonal Products

Does Honest (HNST) Buyback Plan Signal Capital Discipline Or Mask Deeper Growth Challenges?

The Honest Company, Inc. recently reported that full-year 2025 sales slipped to US$371.32 million while net loss more than doubled to US$15.69 million, and simultaneously announced a new US$25 million share repurchase program funded by cash on hand and operating cash flows. Alongside this, management issued 2026 guidance calling for an anticipated high-teens percentage decline in reported revenue due to exited categories, while emphasizing 4% to 6% organic growth as the core metric of its...
NYSE:VZ
NYSE:VZTelecom

How Verizon’s €2.25 Billion Junior Debt Sale Will Impact Verizon Communications (VZ) Investors

In February 2026, Verizon Communications Inc. completed the sale of €2.25 billion and £600 million of junior subordinated unsecured notes due 2056, including step-up and fixed-to-floating rate Eurobonds that are callable and carry a 0.65% discount to par. This move adds long-dated, junior capital to Verizon’s balance sheet, potentially supporting funding for network investment and ongoing transformation without immediately relying on common equity. We’ll now examine how this large junior...
NYSE:LUV
NYSE:LUVAirlines

Assessing Southwest Airlines (LUV) Valuation After A Sharp Multi‑Month Share Price Rebound

What Southwest Airlines (LUV) investors may be watching now Recent trading in Southwest Airlines (LUV) has drawn attention after a sharp move in the share price over the past month and past 3 months, prompting investors to reassess the airline’s current valuation and fundamentals. See our latest analysis for Southwest Airlines. At a share price of US$49.26, Southwest Airlines has seen a 30 day share price return of 20.56% and a 90 day share price return of 41.51%, while the 1 year total...
NYSE:EVR
NYSE:EVRCapital Markets

Has Evercore (EVR) Pullback Created A Fresh Opportunity For Long‑Term Investors

If you are wondering whether Evercore's current share price fairly reflects its underlying worth, you are not alone. This article is designed to help you size that up clearly. The stock last closed at US$308.84, with returns of 29.2% over 1 year and a 144.5% gain over 3 years, even though the past 7 days and 30 days show declines of 5.9% and 15.0% and the year to date return sits at a 12.1% decline. Recent coverage has focused on Evercore's role as a major independent investment bank in...
NasdaqCM:SEZL
NasdaqCM:SEZLDiversified Financial

Sezzle (SEZL) Is Up 16.3% After 2025 Earnings Beat And Sezzle Mobile Launch Guidance – Has The Bull Case Changed?

In February 2026, Sezzle Inc. reported full-year 2025 results showing sales of US$450.28 million and net income of US$133.13 million, alongside guidance for 2026 calling for total revenue growth of 25% to 30% and the launch of Sezzle Mobile, an integrated unlimited phone plan starting at US$29.99 per month within its app. These updates highlight Sezzle’s shift from a pure buy-now-pay-later platform toward a broader financial and everyday-spending hub, with subscription, payments, and now...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing (QUBT) Is Up 6.5% After Luminar Deal, NASA Wins And First Bank Cyber Sale - What's Changed

In recent months, Quantum Computing Inc. (QCi) raised US$1.25 billion in cash, closed a US$110.0 million acquisition of Luminar Semiconductor, secured contracts with NASA and NIST, completed a quantum photonic chip foundry in Tempe, Arizona, and announced it would report Q4 and full-year 2025 results on March 2, 2026. These moves, alongside the company’s first U.S. commercial sale of quantum cybersecurity solutions to a top-five bank and growing Department of Defense work, highlight QCi’s...
NasdaqGM:SYM
NasdaqGM:SYMMachinery

Assessing Symbotic (SYM) Valuation After Strong Q1 Beat And Raised Earnings Outlook

Symbotic (SYM) is back in focus after reporting first quarter results that exceeded expectations on both profitability and revenue, supported by improved margins and what management describes as strong operational execution. See our latest analysis for Symbotic. At a share price of $54.78, Symbotic has seen a 90 day share price return decline of 34.61%. Its 1 year total shareholder return of 141.32% and 3 year total shareholder return of about 3.3x point to strong longer term momentum despite...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

Is It Too Late To Reassess Vistance Networks (VISN) After Its 176% One Year Surge?

If you are wondering whether Vistance Networks at around US$17.57 still offers value after a strong run, this article will help you size up the price against the fundamentals. The stock has pulled back with a 7.4% decline over the last week and a 6.5% decline over the last 30 days, yet it still sits on a 176.7% return over the past year and 125.3% over three years. Recent price moves come as the market continues to react to ongoing news flow around Vistance Networks, including growing...
NasdaqGS:ACT
NasdaqGS:ACTDiversified Financial

New Buybacks And Credit Line Might Change The Case For Investing In Enact Holdings (ACT)

Enact Holdings, Inc. has recently outlined in its 2025 10-K a new US$350 million share repurchase authorization and a US$435 million revolving credit facility, alongside continued plans to return capital via dividends and buybacks while supporting its U.S. mortgage insurance operations. Analyst sentiment has shifted as Enact was elevated to a Zacks Rank #1 (Strong Buy) on the back of higher earnings estimates, underscoring how its capital return plans and financing flexibility are...
NYSE:MRSH
NYSE:MRSHInsurance

Dividend Hike, Injunction and New Director Might Change The Case For Investing In Marsh & McLennan (MRSH)

In late February 2026, Marsh & McLennan Companies’ board declared a US$0.900 quarterly dividend per share and secured a court injunction protecting its confidential information, while also adding experienced investment executive Peter Harrison to its now 13‑member board. Together, the legal victory, board refresh, and continued capital return program underscore how Marsh & McLennan is reinforcing both its governance framework and protection of core client and data relationships. We’ll now...
NYSE:TNK
NYSE:TNKOil and Gas

Does Teekay Tankers (TNK) Balancing Strong Q4 Profits With a Steady Dividend Reveal Its Strategy?

Teekay Tankers Ltd. reported past fourth quarter 2025 revenue of US$258.27 million, with net income rising to US$120.46 million and diluted earnings per share from continuing operations of US$3.46, while full-year 2025 revenue was US$951.80 million and net income was US$351.19 million. Despite lower full-year revenue and earnings compared with the prior year, the company’s stronger quarterly profitability and the Board’s decision to maintain a regular US$0.25 per-share cash dividend for the...
NYSE:ACI
NYSE:ACIConsumer Retailing

Albertsons Adds Tech Leader Brian Rice As Board Focuses On Digital Execution

Albertsons Companies (NYSE:ACI) has appointed experienced technology executive Brian Rice to its Board of Directors. Rice brings a background in digital transformation, technology leadership, and global supply chain operations at major consumer brands including McDonald's. The board change highlights a focus on technology, digital engagement, and cybersecurity for the grocery retailer. Albertsons, one of the largest food and drug retailers in the United States, operates a wide network of...
NasdaqGS:NDSN
NasdaqGS:NDSNMachinery

Nordson Insider Sales Test Confidence After Strong Quarter And Upbeat Guidance

Nordson (NasdaqGS:NDSN) reported strong Q1 earnings, followed by several analyst upgrades. Shortly after these results, the CEO and Executive Vice President executed significant insider share sales. The timing of these transactions, coming on the heels of upbeat quarterly news, has drawn investor attention. Nordson, a producer of precision dispensing and related technologies, operates at the intersection of industrial, electronics, and consumer end markets. Many of its customers use Nordson...